Key facts
- A world lead within diabetes and haemostasis management
- Sales totalled DKK 51.1 billion in 2009 (Eur 6.9 billion)
- In 2009 total insulin market of 51% and modern insulin market share 45%, measured by volume (Source IMS)
- Some 28,800 Full time employees
- Focus on core areas with large unmet medical needs: Diabetes care, haemostasis, growth hormone disorders and other biopharmaceuticals
- Strong global marketing network
- Listed on NASDAQ OMX Copenhagen and New York Exchanges
